Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

Nature Medicine

Volumn 3, Issue 9, 1997, Pages 984-989

  Cantwell, Mark ^a   Hua, Tinh ^a   Pappas, Jim ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; LIGAND;

ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD3; ANTIGENS, CD40; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; DNA PRIMERS; DOWN-REGULATION; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SOLUBILITY;

EID: 0030846220     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0997-984     Document Type: Article

References (46)

1. + T cells. J. Immunol. 151, 2497-251 0(1993).
2. Castle, B.E., Kishimoto, K., Stearns, C., Brown, M.L. & Kehry, M.R. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J. Immunol. 151, 1777-1788 (1993).
3. Banchereau, J. et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881-922 (1994).
4. Clark, E.A. & Ledbetter, J.A. How B and T cells talk to each other. Nature 367, 425-428 (1994).
5. Van den Eertwegh, A.J. et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178, 1555-1565 (1993).
6. + memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex J. Exp. Med. 181, 1293-1301 (1995).
7. Han, S. et al. Cellular interaction in germinal centers: Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155, 556-567 (1995).
8. Aruffo, A. et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72, 291-300 (1993).
9. Allen, R.C. et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259, 990-993 (1993).
10. DiSanto, J.P., Bonnefoy, J.Y., Gauchat, J.F., Fischer, A. & de Saint Basile, G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 361, 541-543 (1993).
11. Korthauer, U. et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361, 539-541 (1993).
12. Crewal, I.S., Xu, J. & Flavell, R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378, 617-620 (1995).
13. Kipps, T.J. Chronic lymphocytic leukemia and related diseases. in William's Hematology. (eds. Beutler, E., Lichtman, M.A., Coller, B.S. & Kipps, T.J.) 1017-1039 (McGraw-Hill, Inc., New York, 1995).
14. Hamblin, T.J., Oscier, D.G. & Young, B.J. Autoimmunity in chronic lymphocytic leukaemia. J. Clin. Pathol. 39, 713-716 (1986).
15. Westbrook, C.A. & Golde, D.W. Clinical problems in hairy cell leukemia: Diagnosis and management. Semin. Oncol. 11, 514-522 (1984).
16. Rosen, F.S., Cooper, M.D. & Wedgwood, R.J. The primary immunodeficiencies. N. Engl. J. Med. 333, 431-440 (1995).
17. Lucivero, G., Prchal, J.T., Lawton, A.R., Antonaci, S. & Bonomo, L. Abnormal T-cell functions in B-cell chronic lymphocytic leukemia do not imply T-lymphocyte involvement in the leukemic process: Report of a case with demonstrated "polyclonality" of T lymphocytes. J. Clin. Immunol. 3, 111-116 (1983).
18. Han, T. et al. Lack of autologous mixed lymphocyte reaction in patients with chronic lymphocytic leukemia: Evidence for autoreactive T-cell dysfunction not correlated with phenotype, karyotype, or clinical status. Blood 60, 1075-1081 (1982).
19. Kay, N.E. & Kaplan, M.E. Defective T cell responsiveness in chronic lymphocytic leukemia: Analysis of activation events. Blood 67, 578-581 (1986).
20. Kay, N.E. & Kaplan, M.E. Defective expression of T cell antigens in chronic lymphocytic leukaemia: Relationship to T cell dysfunction. Br. J. Haematol. 57, 105-111 (1984).
21. Ayanlar-Batuman, O., Ebert, E. & Hauptman, S.P. Defective interleukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety. Blood 67, 279-284 (1986).
22. Fernandez, L.A., MacSween, J.M. & Langley, G.R. T cell function in untreated B cell chronic lymphocytic leukemia. Cancer 39, 1168-1174 (1977).
23. Platsoucas, C.D. et al. Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: Augmentation by in vitro treatment with interferon. J. Immunol. 125, 1216-1223 (1980).
24. Callery, R.T. et al. Functional abnormalities associated with T lymphocytes from patients with chronic lymphocytic leukemia. Clin. Immunol. Immunopathol. 17, 451-458 (1980).
25. Semenzato, G., Pezzutto, A., Agostini, C., Albertin, M. & Gasparotto, G. T-lymphocyte subpopulations in chronic lymphocytic leukemia: A quantitative and functional study. Cancer 48, 2191-2197 (1981).
26. Matutes, E., Wechsler, A., Gomez, R., Cherchi, M. & Catovsky, D. Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br. J Haematol. 49, 635-642 (1981).
27. Totterman, T.H., Carlsson, M., Simonsson, B., Bengtsson, M. & Nilsson, K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 74, 786-792 (1989).
28. + cells in IgE production. J. Immunol. 156, 1781-1787 (1996).
29. Lotz, M., Ranheim, E. & Kipps, T.J. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J. Exp. Med. 179, 999-1004 (1994).
30. van Kooten, C. et al. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur. J. Immunol. 24, 787-792 (1994).
31. Grammer, A.C. et al. The CD40 ligand expressed by human B cells costimulates B cell responses. J. Immunol. 154, 4996-5010 (1995).
32. Yellin, M.J. et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J. Immunol. 152, 598-608 (1994).
33. Storrie, B. & Edelson, P.J. Distribution of concanavalin A in fibroblasts: Direct endocytosis versus surface capping. Cell 11, 707-717 (1977).
34. Salisbury, J.L., Condeelis, J.S. & Satir, P. Role of coated vesicles, microfilaments and calmodulin in receptor-mediated endocytosis by cultured B lymphoblastoid cells. J. Cell Biol. 87, 132-141 (1980).
35. Ranheim, E.A. & Kipps, T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177, 925-935 (1993).
36. Notarangelo, L.D., Duse, M. & Ugazio, A.C. Immunodeficiency with hyper-IgM (HIM). Immunodefic. Rev. 3, 101-121 (1992).
37. Rossi, E. et al. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 10, 494-497 (1996).
38. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798 (1992).
39. Bowen, F., Haluskey, J. & Quill, H. Altered CD40 ligand induction in tolerant T lymphocytes. Eur. J. Immunol. 25, 2830-2834 (1995).
40. Hermann, P. et al. Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes. Eur. J. Immunol. 23, 961-964 (1993).
41. Paulie, S. et al. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother. 20, 23-28 (1985).
42. Ben-Aissa, H. et al. Human bladder cancer associated antigens: evaluation of antigenicity in TCC tissues of different grades and in normal urothelium. Anticancer. Res. 8, 443-449 (1988).
43. Hutchins, D. & Steel, C.M. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int. J. Cancer 58, 80-84 (1994).
44. Pammer, J. et al. CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. Am. J. Pathol. 148, 1387-1396 (1996).
45. + CTL response. J. Exp. Med. 183, 2129-2142 (1996).
46. Stuber, E., Strober, W. & Neurath, M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183, 693-698 (1996).